Inicio・Lista de Acciones・Genmab A-S

Genmab A-S

Cerrado

1,876.5 -0.98

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1872.5

Máximo

1910.5

Métricas clave
By Trading Economics
Ingresos	21M 52M
Ventas	-169M 896M
P/B Media del Sector	21.345 62.58
BPA	8.48
Margen de beneficios	5.818
Empleados	3,088
EBITDA	-30M 215M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-1.49% downside

Dividendos
By Acuity
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	8.6B 113B
Apertura anterior	1877.48
Cierre anterior	1876.5

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 jul 2026, 23:56 UTC

Fox Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains stable within its one-month trading range.

24 jul 2026, 23:56 UTC

Lumen Technologies Inc shares are higher in after-market trading, continuing fluctuations despite a broader trend of declines over the past month. No specific news identified.

24 jul 2026, 23:56 UTC

Correlated Moves

State Street Corp shares are lower in after-market trading, reflecting broader market dynamics amid turmoil in the bond markets and sector trends.

24 jul 2026, 23:56 UTC

Wingstop Inc. shares are higher in after-market trading, recovering from an earlier dip. The stock remains near the lower end of its one-month range.

24 jul 2026, 23:56 UTC

Cracker Barrel Old Country Store shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market conditions.

24 jul 2026, 23:56 UTC

Carpenter Technology Corp shares are lower in after-market trading, reflecting broader market trends amid rising concerns in the bond markets.

24 jul 2026, 23:56 UTC

CMS Energy shares are higher in after-market trading following a slight pullback earlier in the session. The stock has advanced since Friday's close.

24 jul 2026, 23:56 UTC

DocuSign Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid narrow trading fluctuations and no specific news.

24 jul 2026, 23:56 UTC

JD.Com shares were lower in after-market trading, despite briefly peaking shortly after market open. The stock remains near the upper end of its one-month range.

24 jul 2026, 23:56 UTC

Correlated Moves

Ares Capital Corp shares declined slightly in after-market trading, reflecting broader financial sector trends amid turmoil in bond markets and rising spreads.

24 jul 2026, 23:56 UTC

Correlated Moves

ON Semiconductor shares are higher in after-market trading, tracking MACOM's advance. The stock remains near the lower end of its one-month range.

24 jul 2026, 23:56 UTC

Aptiv PLC shares are trading higher in after-market hours, remaining near the lower end of their one-month trading range. No specific news was identified.

24 jul 2026, 23:56 UTC

The iShares MSCI South Korea ETF is trading lower in after-market hours, continuing a decline since Friday's close. No specific news was identified.

24 jul 2026, 23:52 UTC

S&P/Case-Shiller Home Price Index Set to Show 5.2% Increase Amid Mixed Economic Sentiment and Rising Inflation Concerns

24 jul 2026, 23:52 UTC

South Africa's Upcoming Balance of Trade Data Sparks Caution Amid First Trade Deficit and Global Supply Chain Tensions.

24 jul 2026, 23:51 UTC

UnitedHealth Group Inc shares are lower in after-market hours, continuing a decline since Friday's close amid broader market trends. No specific news was identified.

24 jul 2026, 23:51 UTC

Wendy's Co shares are higher in after-market hours, continuing an upward trend from earlier in the session, despite no specific news driving the move.

24 jul 2026, 23:51 UTC

Pilgrim's Pride Corp shares are higher in after-market trading, continuing gains from Friday's close and nearing the upper end of their one-month trading range.

24 jul 2026, 23:51 UTC

Axon Enterprise Inc shares are trading lower in after-market hours, reaching a session low amid broader turmoil in bond markets affecting credit investors.

24 jul 2026, 23:51 UTC

Clear Secure Inc shares are higher in after-market trading, recovering from an initial dip. The stock remains near the lower end of its one-month range.

24 jul 2026, 23:51 UTC

indie Semiconductor Inc. shares were roughly flat in after-market hours, following four consecutive daily declines amid ongoing market challenges.

24 jul 2026, 23:51 UTC

Howmet Aerospace Inc shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the move.

24 jul 2026, 23:51 UTC

Trimble Inc shares are higher in after-market trading, showing resilience despite challenging macroeconomic conditions and no specific company news identified.

24 jul 2026, 23:51 UTC

Constellation Brands Inc shares are higher in after-market hours, reflecting modest gains since Friday's close despite broader bond market turmoil.

24 jul 2026, 23:51 UTC

East West Bancorp Inc shares are higher in after-market trading, reflecting notable strength since Friday's close, with no specific news identified.

24 jul 2026, 23:51 UTC

U.S. equity indices remain flat as investors weigh mixed earnings, geopolitical tensions, and a surprising drop in jobless claims amidst rising oil prices.

24 jul 2026, 23:51 UTC

Global equity markets show mixed performance as European indices rise on positive economic data, while Asian markets decline amid geopolitical tensions and rising oil prices.

24 jul 2026, 23:51 UTC

European equity indices rebound on strong PMI data, while Asian markets decline amid rising oil prices and geopolitical tensions.

24 jul 2026, 23:51 UTC

Asian equity markets decline amid rising oil prices and geopolitical tensions, while Germany's DAX rises; U.S. stocks remain flat as investors await key economic data.

24 jul 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Genmab A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.